V
Victoria M. Villaflor
Researcher at Northwestern University
Publications - 135
Citations - 3524
Victoria M. Villaflor is an academic researcher from Northwestern University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 27, co-authored 108 publications receiving 2918 citations. Previous affiliations of Victoria M. Villaflor include Rush University Medical Center & City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer
Ezra E.W. Cohen,Theodore Karrison,Masha Kocherginsky,Jeffrey Mueller,Robyn Egan,Chao H. Huang,Bruce Brockstein,Mark Agulnik,Bharat B. Mittal,Furhan Yunus,Sandeep Samant,Luis E. Raez,Ranee Mehra,Priya Kumar,Frank G. Ondrey,Patrice Marchand,Bettina Braegas,Tanguy Y. Seiwert,Victoria M. Villaflor,Daniel J. Haraf,Everett E. Vokes +20 more
TL;DR: The study was underpowered because it did not meet the planned accrual target, and OS was higher than predicted in both arms, but IC cannot be recommended routinely in patients with N2 or N3 locally advanced SCCHN.
Journal ArticleDOI
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
Joseph K. Salama,Michael D. Hasselle,Steven J. Chmura,Renuka Malik,Neil Mehta,Kamil M. Yenice,Victoria M. Villaflor,Walter M. Stadler,Philip C. Hoffman,Ezra E.W. Cohen,Philip P. Connell,Daniel J. Haraf,Everett E. Vokes,Samuel Hellman,Ralph R. Weichselbaum +14 more
TL;DR: A subset of patients with metastatic cancer in limited organs may benefit from metastasis‐directed therapy, and the authors investigated whether patients with limited metastases could be safely treated with metastasis-directed radiotherapy.
Journal ArticleDOI
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.
Young Kwang Chae,Keerthi Ranganath,Peter S. Hammerman,Christos Vaklavas,Nisha Mohindra,Aparna Kalyan,Maria Matsangou,Ricardo Costa,Benedito A. Carneiro,Victoria M. Villaflor,Massimo Cristofanilli,Francis J. Giles +11 more
TL;DR: This review aims to consolidate data from recent clinical trials with a focus on selective FGFR inhibitors, with the hope that overcoming current barriers will expedite the availability of this novel class of medications.
Journal ArticleDOI
Phase 2 study of sunitinib in refractory thyroid cancer
Ezra E.W. Cohen,B. M. Needles,Kevin J. Cullen,Stuart J. Wong,James L. Wade,S. P. Ivy,Victoria M. Villaflor,Tanguy Y. Seiwert,K. Nichols,Everett E. Vokes +9 more
TL;DR: This data indicates that sunitinib, has inhibitory activity against RET, VEGFR, and PDG FR, and thus has potential to be active in both DTC and MTC, and may help patients with refractory differentiated and medullary thyroid cancers.
Journal ArticleDOI
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
Tanguy Y. Seiwert,Corey C. Foster,Elizabeth A. Blair,Theodore Karrison,Nishant Agrawal,J.M. Melotek,Louis G. Portugal,Ryan J. Brisson,Allison Dekker,Sara Kochanny,Zhen Gooi,Mark W. Lingen,Victoria M. Villaflor,Daniel Thomas Ginat,Daniel J. Haraf,Everett E. Vokes +15 more
TL;DR: Induction chemotherapy with response and risk-stratified dose and volume de-escalated RT/CRT for HPV+ OPSCC is associated with favorable oncologic outcomes and reduced acute and chronic toxicity.